6:28 PM
 | 
Nov 13, 2012
 |  BC Extra  |  Top Story

Dynavax up on Heplisav briefing docs

Dynavax Technologies Corp. (NASDAQ:DVAX) gained $0.56 (13%) to $4.74 on Tuesday after FDA reviewers said the company's HBV product Heplisav showed non-inferiority and a comparable safety profile to a marketed HBV vaccine. In the pivotal Phase III DV2-HBV-10 and DV2-HBV-16 trials, Heplisav met the primary endpoint of a non-inferior seroprotection rate at week 12 compared to Engerix-B...

Read the full 276 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >